Moneycontrol Bureau:
A subsidiary of Sun Pharmaceutical Industries has received approval from the US Foods and Drugs Administration for its new drug application (NDA) for anti-cancer Docefrez (Docetaxel) injection. This NDA provides for the use of Docefrez injection for locally advanced or metastatic breast cancer, non-small cell lung cancer and hormone refractory metastatic prostate cancer, Sun Pharma said in a notice to the stock exchanges. Sun Pharma shares recovered from a low of Rs 435 following the announcement, and at 14:00 hrs were trading at Rs 442.05 on National Stock Exchange, down 1.4% on National Stock Exchange. Docefrez is the generic version of French company Sanofi AventisDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
